(Q37993110)

English

Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice

scientific article published on March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1 reference

based on heuristic

inferred from title

stem cell transplantation

1 reference

based on heuristic

inferred from title

Thomas Lehrnbecher

3

object named as

Thomas Lehrnbecher

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Andreas H Groll

4

object named as

Andreas H Groll

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Athanasios Tragiannidis

1

object named as

Athanasios Tragiannidis

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

author name string

Charalampos Dokos

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

1 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

72

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

685-704

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

https://scigraph.springernature.com/pub.10.2165/11599810-000000000-00000

0 references

Risk factors for disseminated candidiasis in children with candidemia

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Risk factors for mortality in children with candidemia

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Zygomycetes infections in pediatric hematology oncology patients: a case series and review of the literature.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Invasive fungal infections in pediatric oncology.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Diagnosis of invasive fungal infections in immunocompromised children

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Recent advances in antifungal prevention and treatment

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Recommendations for broader coverage antifungal prophylaxis in childhood acute myeloid leukemia: ASH evidence-based review 2011.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Aspergillosis case-fatality rate: systematic review of the literature

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: Results from a multi-center Italian study

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Candidaemia in a European Paediatric University Hospital: a 10-year observational study.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Invasive candidosis in pediatric patients.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Epidemiology of invasive fungal infections in neonates and children

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Increasing Incidence of Mucormycosis in University Hospital, Belgium

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Safety experience with caspofungin in pediatric patients.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Update on antifungal agents for paediatric patients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Clinical pharmacology of antifungal compounds

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

New dosing strategies for liposomal amphotericin B in high-risk patients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Posaconazole plasma concentrations in juvenile patients with invasive fungal infection

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Antifungal prophylaxis with micafungin in patients treated for childhood cancer.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Impact of previous aspergillosis on the outcome of bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of th

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Posaconazole salvage treatment in paediatric patients: a multicentre survey

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Changing epidemiology of systemic fungal infections.

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Infections diagnosed in the first year after pediatric stem cell transplantation

2 references

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients

1 reference

https://api.crossref.org/works/10.2165%2F11599810-000000000-00000

21 January 2018

Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nosocomial infections and multidrug-resistant organisms in Germany: epidemiological data from KISS (the Hospital Infection Surveillance System).

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of micafungin in pediatric clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of fluconazole in pediatric patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Candida non-albicans versus Candida albicans fungemia in the non-neonatal pediatric population

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and tolerability of fluconazole in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug therapy in paediatric patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and pharmacokinetics of fluconazole in children with neoplastic diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22413762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11599810-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37993110&oldid=2111804520"